New triple attack on rare melanoma shows promise in early trial
NCT ID NCT07236528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy as a first treatment for advanced mucosal melanoma, a rare and aggressive skin cancer. The study will enroll 30 adults who have not had prior systemic therapy. Researchers will measure how long the cancer stays under control and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carilizumab (immunotherapy), Apatinib mesylate (targeted drug), and radiotherapy
What this could lead to
If it works, this could offer a new first-line treatment option for advanced mucosal melanoma, potentially improving how long the cancer is kept under control.
What could go wrong
This is a small, early-phase trial (30 people) with no control group, so results may not be definitive. The combination of three treatments may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••